All these experimental findings indicate that Gal-3 emerges not only as a key player in the pathogenesis of RA [385], but also as a novel potential therapeutic target and implicate that down-regulation of Gal-3 may represent novel a therapeutic strategy for RA. The gene discussed is LGALS3; the disease is rheumatoid arthritis.